Search | Page 4 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS)

    ... aim of treatment is to improve anemia and decrease red blood cell transfusions. For transfusion-dependent patients with lower-risk ...

    Research Article last updated 12/09/2016 - 2:50pm.

  2. Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis

    ... Lenalidomide could effectively induce red blood cell (RBC) transfusion independence (TI) in patients with ...

    Research Article last updated 11/28/2016 - 9:36am.

  3. MDS expert finds promising antibody

    ... Researchers find new way to target blood stem cell cancers Article ... of leukemic stem cells become incapable of maturing into red or white blood cells as intended. Most leukemias respond initially to ...

    Article last updated 01/26/2017 - 1:14pm.

  4. Strong results for SAA patients at Johns Hopkins

    ... regimen, published online Dec. 22, 2016, in Biology of Blood and Marrow Transplantation, the Johns Hopkins team says that more than a ... bone marrow cells, which gradually stop producing red and white blood cells and platelets. Patients must receive frequent ...

    Article last updated 02/07/2017 - 11:05am.

  5. Optimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502) (CHAMP)

    ... phase II study with one arm receiving unrelated cord blood transplantation and the other arm receiving haploidentical ... separately in the 2 arms at 1 year post-hematopoietic stem cell transplantation (HSCT). ... of 4.0 x10^7/kg (sum of unit 1 and unit 2). For non- red blood cell depleted units, the minimum pre-cryopreserved TNC dose is ...

    Clinical Trial last updated 12/19/2017 - 7:55am.

  6. Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic Anemia

    ... Journal Title:  Biol Blood Marrow Transplant Primary ... for 3 consecutive days was 19 (range, 16 to 27) days, to red cell engraftment was 25 (range, 2 to 58) days, and to last ...

    Research Article last updated 01/24/2017 - 10:04am.

  7. Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response

    ... Erythropoiesis-stimulating agents (ESAs) reduce red blood cell (RBC) transfusions in approximately 40% of patients with ...

    Research Article last updated 05/26/2015 - 11:49am.

  8. Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes

    ... Low endogenous erythropoietin levels and limited red blood cell transfusion history can predict response to ...

    Research Article last updated 08/04/2014 - 8:33am.

  9. Platelet drug shows clinical benefits for severe, unresponsive aplastic anemia

    ... on our trial went on successfully to have allogeneic stem cell transplantation. Are there any side effects? Very few. At ... National Institutes of Health, National Heart, Lung, and Blood Institute ...

    Interview last updated 07/06/2012 - 3:42pm.

  10. Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and po

    ... and/or thrombocytopenia who may have required red blood cell or platelet transfusions. The overall response rate was ...

    Research Article last updated 06/23/2016 - 10:17am.